| Literature DB >> 22171311 |
Muhammad Akhlaq1, Gul Majid Khan, Abdul Wahab, Arshad Khan, Abid Hussain, Asif Nawaz, Hamdy Abdelkader.
Abstract
A simple, rapid, sensitive, and specific high-performance liquid chromatography (HPLC) assay for flurbiprofen has been developed and validated practically. The chromatography was conducted using Gemini C18 column (5 μm; 4.6 mm × 250 mm, Phenomenex, California, USA). The mobile phase containing disodium hydrogen phosphate solution (30 mM) pH 7.0 and acetonitrile (50:50); and the isocratic flow rate of 1.0 ml/min were used in the current study. Detection was made at 247 nm. The calibration curve was linear (r ≥ 0.9996) over the concentration range of 5-50 μm/ml. Mean percentage (%) recovery ± % relative standard deviation (RSD) ranged from 97.07 ± 0.008 to 103.66 ± 0.013. Within-day and between-day precision were also in acceptable range of 98.83 ± 0.004 to 104.56 ± 0.009. In order to confirm the practical applicability of the method developed, flurbiprofen controlled release matrix tablets were subjected to the dissolution studies and the release rate was analyzed. The reported HPLC for flurbiprofen provides several advantages of simplicity, high specificity, accuracy, and very short run-cycle time. It is suggested that the method should be used for the routine quality control analysis of flurbiprofen pure drug and its dosage forms.Entities:
Keywords: Chromatography; flurbiprofen; isocratic; quality control; validation
Year: 2011 PMID: 22171311 PMCID: PMC3217703 DOI: 10.4103/2231-4040.85529
Source DB: PubMed Journal: J Adv Pharm Technol Res ISSN: 0976-2094
Figure 1Representative HPLC chromatograms for FLB at three different concentrations in mobile phase
Reverse predicted concentrations, % recovery and regression coefficient (R2)
Precision and accuracy data of the QC samples (Results were expressed as mean values, n = 5)
Figure 2PDA-absorption spectra of the FLB peak from a standard solution
Figure 3Mean standard HPLC calibration curve for FLB (n = 5)
Figure 4FLB release data from two selected controlled release matrix tablets